Winkler V
Orv Hetil. 1989 Jan 8;130(2):77-81.
In the past few years several reports have been published on the favourable effect of sulphasalazine in ankylosing spondylitis. This induced us to compare sulphasalazine with placebo in a prospective, randomized single-blind trial in 63 patients with active ankylosing spondylitis. After termination of the 24 week course of treatment significant improvement was registered in several clinical parameters both in the group taking the active drug (31 patients) and in that on placebo (32 patients). The advantage of sulphasalazine over placebo only proved to be significant in the duration of articular morning stiffness and in reducing disturbances of sleep. Observations claiming sulphasalazine to act as a remission inducing drug for ankylosing spondylitis have neither been confirmed nor ruled out by our experiences. Accurate appraisal of the effectiveness of sulphasalazine still calls for further extensive placebo-controlled double-blind studies.
在过去几年里，已有多篇关于柳氮磺胺吡啶对强直性脊柱炎有良好疗效的报道。这促使我们在一项前瞻性、随机单盲试验中，将柳氮磺胺吡啶与安慰剂进行比较，该试验共有63例活动性强直性脊柱炎患者参与。在为期24周的治疗疗程结束后，服用活性药物的组（31例患者）和服用安慰剂的组（32例患者）的多项临床参数均有显著改善。柳氮磺胺吡啶相对于安慰剂的优势仅在关节晨僵持续时间和减少睡眠障碍方面被证明具有显著性。关于柳氮磺胺吡啶可作为强直性脊柱炎缓解诱导药物的观点，我们的经验既未证实也未排除。对柳氮磺胺吡啶有效性的准确评估仍需要进一步广泛的安慰剂对照双盲研究。
